Know Cancer

or
forgot password

Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer


N/A
26 Years
85 Years
Not Enrolling
Both
Squamous Cell Carcinoma

Thank you

Trial Information

Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer


MATERIAL AND METHODS

After approval by the Hospital Review Board, we obtained formalin-fixed, paraffin-embedded
specimens from 115 patients with primary oral SCC and 66 patients with oral ED at the
Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Diagnosis of
oral SCC and ED was based on histological examination of hematoxylin and eosin-stained
tissue sections. All patients received total surgical excision of the lesions at the
Department of Oral and Maxillofacial Surgery or Department of Otolaryngology, National
Taiwan University Hospital during the period from 1997 to 2004. Specimens were obtained
from either incisional biopsies or total surgical excision of the lesions. If lymph node
was diagnosed as positive for SCC, neck dissection and postoperative radiation therapy were
also included in the treatment protocol. No patient had received any cancer therapy before
initial biopsies. Details of the patients’ oral habits, including daily consumption of AQs,
cigarettes, and alcohol as well as the duration of these habits, were also recorded in the
medical chart. Twenty biopsy specimens of normal oral mucosa (NOM) were obtained from
non-AQ-chewers and non-smokers during extraction of impacted permanent lower third molars
after obtaining informed consent, and used as the healthy controls.

Cell culture Dulbecco’s modifed Eagle’s medium (DMEM), and fetal bovine serum (FBS) were
purchased from Life Technologies, Inc. (Gaithersburg, MD,USA). PD98059, Ly294002, SB203580
and Hepatocyte growth factor (HGF) were products of Sigma (St Louis, MO, USA). Anti-ANX-1
monoclonal antibody was purchased from BD Biosciences (Lexington, KY, USA). Cell culture SAS
cells were maintained in DMEM supplemented with 10% heat-inactivated FBS, penicillin (100
UAmL)1), and streptomycin (100 lgAmL)1) at 37 o C under 5% CO2 atmosphere. For Western blot
analysis, cells were seeded into 10 cm dishes at 2 x 106 cells per dish. After 18–24 hr,
cells were further grown in the same medium supplemented without FBS for 24 h. Serum-starved
cells were treated with HGF in the indicated times. For immunostaining, 2 x 105 cells grown
on cover slides (22 x 22 mm) were starved for 24 h before stimulation with HGF.

Pre-treatment with PD098059, Ly294002 and SB203580 The cells were plated overnight in
complete medium and then washed. The cells cultured in serum-free DMEM were pre-treated with
50M PD098059 (inhibitor of ERK), 30 M Ly294002( inhibitor of PI-3 kinase) and 20 M
SB203580(inhibitor of p38) for 3 hrs respectively, and then they were treated with 40ng HGF
for 3hrs. The cells were checked by immunohistochemistry and Western blot with ANXA1
antibody.

Immunocytochemistry(IHC) Formalin-fixed, paraffin-embedded tumor samples were assessed for
annexin A1 expression.The IHC procedures was followed as the reference18, The monoclonal
primary antibody anti-Annexin AI(1:600 dilution), directed against the the N-terminus of
annexin 1 were obtained from a signal source (BD Biosciences). Protein translocation as
determined by two pathologists (Jeng and Lin) using immunohistochemistry was scored as
negative (score 0), positive (score 1) and cytoplasmic protein expression was scored as
negative (score 0), weak (score 1), moderate (score 2), or strong (score 3) using a system
that has been previously validated.

SAS cells grown on cover slides were fixed with 3.7% paraformaldehyde for 15 min and
permeabilized with 0.2% Triton X-100 in PBS (0.58M Na2HPO4, 0.17 M Na H2PO4, 0.68 M NaCl,
pH=7.4)(PBST) for 5 min. After washing the cells with PBST three times, the cells were
blocked for 30 min in PBS containing 1% bovine serum albumin. Immunostaining was performed
by incubation with anti-ANX-1 monoclonal antibody (1:800 dilution) for 2h. After washing the
cells with PBST three times, the cells were incubated with TRITC-conjugated rabbit
anti-(mouse IgG) Ig for 1 h. Cover slides were washed with PBST, mounted, and examined using
a Leica TCS SP2 Confocal microscope (Leica Microsystems, Wetzlar GmBH, Germany).

Cell fractionation SAS cells were seeded into 10cm dishes at 2x 106 cells/dish and cultured
in DMEM for 18–24 h. The cells were starved for 24 h in serum-free media. After treatment
with HGF for a given time, the cells were harvested and washed with ice-cold PBS. The cells
were then resuspended in 100 lL of lysis buffer (10 mM Hepes, 10 mM NaCl, 0.1 mM EDTA, 0.1
mM EGTA, 1% NP-40, 0.5 mM phenylmethylsulfonyl uoride, 0.1 mM dithiothreitol, 0.1 mM sodium
orthovanadate, and protease inhibitors) and incubated on ice for 10 min. The nuclei were
collected by centrifugation at 2000 g for 5 min at 4 o C. The supernatant was collected as a
cytosolic fraction. Protein concentration of each sample was determined.

Evalution of annexin A1 Protein Expression The distributions of ANXA1 expression in four
categories (0-25%, 26-50%, 51-75% and 76-100%) with nuclear translocation were firstly
showed by clinicopathological parameters of the oral ED and SCCs and the correlations
between mean levels of expression and these clinicopathological parameters were further
examined using ANOVA. The Kaplan-Meier product-limit method was used to assess the
prognostic significance of the ANXA1 nuclear staining in cancer cells as well as other
clinicopathological parameters. Comparison of cumulative survival between groups was
performed using the log-rank test with the Statistica program (StatSoft Inc., USA).
Multivariable analyses were performed with Cox regression model to assess additional
prognostic values of the different variables using SAS 8.0 (SAS Institute Inc., USA). A
P-value of less than 0.05 was considered as statistically significant.


Inclusion Criteria:



noraml, dysplasia, SCC

Exclusion Criteria:

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional, Time Perspective: Retrospective/Prospective

Principal Investigator

Mark YP Kuo, PHD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Taiwan University , Dental Department

Authority:

Taiwan: Department of Health

Study ID:

9561702012

NCT ID:

NCT00364715

Start Date:

January 2005

Completion Date:

December 2005

Related Keywords:

  • Squamous Cell Carcinoma
  • Nuclear localization, annexin A1, oral SCC
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Mouth Neoplasms

Name

Location